EKF has delivered very strong FY21 results, ahead of upgraded expectations. The core business is performing well (+14% YoY) and the investment in expanding the offering is beginning to pay off. However, pandemic-related sales look likely to slow materially and ongoing sales into Russia are proving difficult. We rebase our forecasts accordingly, reducing our FY22E revenue & EBITDA by 26%/40% and by 17%/25% respectively in FY23E. We adjust our TP to 62p (from 86p) and would view any share price we ....
29 Mar 2022
Strong core outlook, Covid & Russia impact ST
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong core outlook, Covid & Russia impact ST
EKF Diagnostics Holdings plc (EKF:LON) | 28.0 0 0.6% | Mkt Cap: 126.8m
- Published:
29 Mar 2022 -
Author:
Chris Glasper -
Pages:
3
EKF has delivered very strong FY21 results, ahead of upgraded expectations. The core business is performing well (+14% YoY) and the investment in expanding the offering is beginning to pay off. However, pandemic-related sales look likely to slow materially and ongoing sales into Russia are proving difficult. We rebase our forecasts accordingly, reducing our FY22E revenue & EBITDA by 26%/40% and by 17%/25% respectively in FY23E. We adjust our TP to 62p (from 86p) and would view any share price we ....